Clinical trial
Cost-utility Analysis of Office Hysteroscopic Morcellation/Aspiration Versus Conventional Operating-room Resectoscopy for Intrauterine Pathologies
NCT07908615 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cost-utility Analysis of Office Hysteroscopic Morcellation/Aspiration Versus Conventional Operating-room Resectoscopy for Intrauterine Pathologies
- Lead sponsor
- Nantes University Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- March 31, 2030
- Enrollment
- 474 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
retained products of conception, uterine fibroids, uterine polyps
Arms
As registered; 2 arms.
-
Operating-room hysteroscopy with resectoscope
Participants undergo operative hysteroscopy using a resectoscope in the operating room, with general or regional anesthesia according to the usual care pathway and clinical decision.
-
Outpatient hysteroscopic morcellation/aspiration
Participants undergo operative hysteroscopy using a morcellation/aspiration system in a dedicated outpatient consultation room, without an operating-room pathway. Analgesia options may include non-steroidal anti-inflammatory medication, local anesthesia, virtual reality and/or an equimolar mixture of oxygen and nitrous oxide, according to participant preference and clinical circumstances.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Incremental cost-utility ratio of outpatient hysteroscopic morcellation/aspiration versus operating-room resectoscopy
Cost-utility analysis comparing the two care pathways from a collective perspective. Costs and quality-adjusted life years (QALYs) derived from EQ-5D-5L measurements will be compared between groups. The incremental cost-utility ratio will be expressed as cost per QALY and results will also be presented as incremental net monetary benefit at different willingness-to-pay thresholds.
Lead sponsor's other trials
Nantes University Hospital, most recent start first.
+833 more trials See the organization page
Similar trials
Same condition (Leiomyoma) and phase, most recent start first.
+135 more trials See the condition page